To open up more clinical paths for patients, HCPs need simpler search tools, better access to information and integrated ...
Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core businessRaising OJEMDA ...
Clovis Raymond, MD, is a psychiatrist, assistant clinical professor of psychiatry at Columbia University, and chief of ...
Q3 2025 Earnings Call Transcript November 3, 2025 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS is $-3.82132 EPS, expectations were $-3.3. Operator: Good morning. My name ...
Abstract available on ASH websiteSAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a ...
Taysha Gene Therapies (TSHA) remains unprofitable and is expected to stay that way for at least the next three years, but has managed to reduce its losses by 7.5% per year over the past five years.
SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...
Sir Charlie Mayfield warned of the economic, human and social costs of ‘lost opportunity, stalled careers, and reduced life ...
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...
TG Therapeutics, Inc. (NASDAQ: TGTX) Q3 2025 Earnings Call Transcript November 3, 2025 TG Therapeutics, Inc. beats earnings ...
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ('Calidi” or the 'Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, ...
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback